Aurothiomalate sodium
Code | Size | Price |
---|
TAR-T20168-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20168-10mg | 10mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20168-25mg | 25mg | £189.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20168-50mg | 50mg | £254.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20168-100mg | 100mg | £369.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T20168-200mg | 200mg | £511.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Aurothiomalate sodium is a potent and selective inhibitor of oncogenic PKC-? signaling. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium exhibits potent anti-tumor activity.
CAS:
12244-57-4
Formula:
C4H3AuNa2O4S
Molecular Weight:
390.07
Pathway:
Chromatin/Epigenetic; Cytoskeletal Signaling;
Purity:
0.98
SMILES:
[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O
Target:
PKC
References
1. Nummenmaa E, H?m?l?inen M, Moilanen LJ, Moilanen T, Vuolteenaho K, Moilanen E. TRPA1 expression is downregulated by dexamethasone and aurothiomalate in human chondrocytes: TRPA1 as a novel factor and drug target in arthritis. RMD Open. 2017 Sep 4;3(2):e000556.
2. Darabi F, Marzo T, Massai L, Scaletti F, Michelucci E, Messori L. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. J Inorg Biochem. 2015 Aug;149:102-7.
3. Tuure L, H?m?l?inen M, Moilanen T, Moilanen E. Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes. Scand J Rheumatol. 2015;44(1):74-9.
4. Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anticancer Drugs. 2014 Mar;25(3):332-9.